2026-02-24
Longevity Biomarkers: What to Test, What the Results Mean, and How to Track Progress
Biological age testing spans conventional labs (HbA1c, CRP, lipids) to newer epigenetic clocks and proteomic aging scores. Most conventional biomarkers are actionable today; epigenetic clocks measure biological vs. chronological age but their clinical utility for intervention-guiding remains limited. A pragmatic panel of validated tests provides meaningful signal about longevity trajectory.
2026-02-24
Testosterone Decline in Men: Natural Trajectory, Functional Impact, and Evidence-Based Support
Testosterone declines approximately 1-2% per year from age 30. The clinical significance of this decline depends on absolute levels and symptoms, not chronological age alone. Testosterone replacement therapy has RCT evidence for improving muscle mass, bone density, and sexual function in men with confirmed hypogonadism. Lifestyle factors significantly modify the trajectory.
2026-02-24
Testosterone Decline in Aging Men: Natural Interventions, Monitoring, and TRT Context
Testosterone declines ~1% per year after age 30 in men. Below clinical thresholds, symptoms include fatigue, sarcopenia, and cognitive fog. Lifestyle interventions (resistance training, sleep, zinc, vitamin D) have the best evidence for supporting endogenous production. Ashwagandha and fenugreek show modest RCT data.
2026-02-21
Longevity Protocol for Women Over 50: Evidence-Based Priorities
Perimenopause and post-menopause mark a major metabolic and hormonal inflection point. This protocol covers the highest-leverage interventions for women over 50, grounded in current evidence.
2026-02-20
Thyroid Function Variability: Selenium, Zinc, and Myo-Inositol in Clinical Context
Thyroid symptom variability should be managed by medication and lab stability first. Selenium, zinc, and myo-inositol may be adjuncts in selected contexts, not primary treatment.